scholarly journals Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by a Recombinant Baculovirus Co-Expressing S1 and N Proteins

Viruses ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 347 ◽  
Author(s):  
Yuan Yuan ◽  
Zhi-Peng Zhang ◽  
Yi-Ning He ◽  
Wen-Sheng Fan ◽  
Zhi-Hua Dong ◽  
...  
Keyword(s):  
Infectious Bronchitis Virus ◽  
Recombinant Baculovirus ◽  
Virus Challenge ◽  
Infectious Bronchitis ◽  
N Proteins

scholarly journals Greater Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by Recombinant Baculovirus Co-expressing S1 and N Proteins

2018 ◽  
Author(s):  
Yuan Yuan ◽  
Zhi-Peng Zhang ◽  
Yi-Ning He ◽  
Wen-Sheng Fan ◽  
Zhi-Hua Dong ◽  
...  
Keyword(s):  
Specific Antibody ◽  
Infectious Bronchitis Virus ◽  
Subunit Vaccine ◽  
Recombinant Baculovirus ◽  
Recombinant Baculoviruses ◽  
Economic Losses ◽  
Subunit Vaccines ◽  
Infectious Bronchitis ◽  
Antibody Levels ◽  
N Proteins

Avian infectious bronchitis virus (IBV) is the causative agent of infectious bronchitis, which causes considerable economic losses to the poultry industry worldwide. It is imperative to develop safe and efficient candidate vaccines to control IBV infection. In the current study, recombinant baculoviruses co-expressing S1 and N proteins, mono-expressing S1 or N proteins alone of IBV were constructed and prepared into subunit vaccines rHBM-S1-N, rHBM-S1 and rHBM-N. The levels of immune protection of these subunit vaccines were evaluated by inoculating specific pathogen-free (SPF) chickens at 14 days of age, boosting with the same dose 14 days later, and following challenge with a virulent GX-YL5 strain of IBV 14 days post-booster (dpb). The commercial vaccine strain H120 was used as a control. The IBV-specific antibody levels as well as the percentages of CD4+ and CD8+ T lymphocytes were detected within 28 days post-vaccination (dpv). The morbidity, mortality, and re-isolation of virus from the tracheas and kidneys of challenged birds were evaluated at 5 days post-challenge (dpc). The results showed that the IBV-specific antibody levels and the percentages of CD4+ and CD8+ T lymphocyte in rHBM-S1-N group were higher than those of rHBM-S1 and rHBM-N groups, especially the cellular immunity response. At 5 dpc, the mortality, morbidity and virus re-isolation rate of rHBM-S1-N were slightly higher than those of H120 group, but were lower than those of rHBM-S1 group and rHBM-N group. The present study demonstrated that the protection of recombinant baculovirus co-expressing S1 and N proteins was better than that of recombinant baculoviruses mono-expressing S1 or N protein alone. Thus, the recombinant baculovirus co-expressing S1 and N proteins could serve as a potential IBV vaccine and this demonstrates that the bivalent subunit vaccine including the S1 and N proteins might be a strategy for the development of an IBV subunit vaccine.

scholarly journals Development of a Recombinant Thermostable Newcastle Disease Virus (NDV) Vaccine Express Infectious Bronchitis Virus (IBV) Multiple Epitopes for Protecting against IBV and NDV Challenges

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 564
Author(s):  
Lei Tan ◽  
Guoyuan Wen ◽  
Yanmei Yuan ◽  
Meizhen Huang ◽  
Yingjie Sun ◽  
...  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Infectious Bronchitis Virus ◽  
Newcastle Disease ◽  
Rural Areas ◽  
Lethal Dose ◽  
Morphological Characteristics ◽  
Ciliary Activity ◽  
Virus Challenge ◽  
Infectious Bronchitis

Newcastle disease (ND) and infectious bronchitis (IB) are two highly contagious diseases that severely threaten the poultry industry. The goal of this study is to prevent these two diseases and reduce the vaccine costs during storage and transportation. In this study, we design a thermostable recombinant Newcastle disease virus (NDV) candidate live vaccine strain designated as rLS-T-HN-T/B, which expresses the multiple epitope cassette of the identified infectious bronchitis virus (IBV) (S-T/B). The rLS-T-HN-T/B strain was found to possess similar growth kinetics, passage stability, morphological characteristics, and virulence to the parental LaSota strain. After incubation at 56 °C at the indicated time points, the rLS-T-HN-T/B strain was determined by the hemagglutination (HA), and 50% embryo infectious dose (EID50) assays demonstrated that it accords with the criteria for thermostability. The thermostable rLS-T-HN-T/B and parental LaSota vaccines were stored at 25 °C for 16 days prior to immunizing the one-day-old specific pathogen-free (SPF) chicks. Three weeks postimmunization, the virus challenge results suggested that the chicks vaccinated with the rLS-T-HN-T/B vaccine were protected by 100% and 90% against a lethal dose of NDV and IBV, respectively. Furthermore, the trachea ciliary activity assay indicated that the mean ciliostasis score of the chicks vaccinated with thermostable rLS-T-HN-T/B vaccine was significantly superior to that of the LaSota and PBS groups (p < 0.05). The rLS-T-HN-T/B vaccine stored at 25 °C for 16 days remained capable of eliciting the immune responses and protecting against IBV and NDV challenges. However, the same storage conditions had a great impact on the parental LaSota strain vaccinated chicks, and the NDV challenge protection ratio was only 20%. We conclude that the thermostable rLS-T-HN-T/B strain is a hopeful bivalent candidate vaccine to control both IB and ND and provides an alternative strategy for the development of cost-effective vaccines for village chickens, especially in the rural areas of developing countries.

Immune Responses to Mucosal Vaccination by the Recombinant S1 and N Proteins of Infectious Bronchitis Virus

2012 ◽  
Vol 25 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Rosie Meir ◽  
Simi Krispel ◽  
Lubov Simanov ◽  
Dalia Eliahu ◽  
Ora Maharat ◽  
...  
Keyword(s):  
Immune Responses ◽  
Infectious Bronchitis Virus ◽  
Infectious Bronchitis ◽  
Mucosal Vaccination ◽  
N Proteins

scholarly journals Virulence Properties of GI-23 Infectious Bronchitis Virus Isolated in Poland and Efficacy of Different Vaccination strategies

Pathogens ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 522
Author(s):  
Anna Lisowska ◽  
Anna Pikuła ◽  
Justyna Opolska ◽  
Agnieszka Jasik ◽  
Anna Kycko ◽  
...  
Keyword(s):  
Infectious Bronchitis Virus ◽  
Middle Eastern ◽  
Economic Losses ◽  
Live Vaccines ◽  
Virus Challenge ◽  
Genetic Lineages ◽  
Infectious Bronchitis ◽  
Age Dependent ◽  
Full Protection ◽  
Virulence Properties

Infectious bronchitis virus (IBV) is one of the most important poultry pathogens, leading significant economic losses worldwide. IBV is characterised by highly genetic, serotype, and pathotypic variability. Despite extensive immunoprophylaxis strategies, the emergence of new genetic lineages is frequently observed in the field, causing disease control to be more complicated. In the last decade, the spread of variants assigned to the GI-23 lineage of IBV (formerly known as Var2) started from Middle-Eastern countries and reached Europe in the last few years. Recently, the introduction and fast spread of Var2-like IBVs in Poland was reported. In this study, the virulence properties and efficacy of different vaccination programmes were evaluated against infection with the IBV GI-23 strain gammaCoV/Ck/Poland/G052/2016. The pathogenicity of the Var2 isolate was conducted in one-day-old and three-week-old SPF chickens and showed that the course of the disease is age dependent. Seven vaccination programmes using Mass, 793B, QX alone or in combination, and Var2 live vaccines were tested against the GI-23 infectious bronchitis virus challenge. All groups were scored according to the ciliostasis test at 5 days post challenge. Two immunoprophylaxis strategies generated full protection against gammaCoV/Ck/Poland/G052/2016 infection—Var2 and Mass used in one-day-old chickens boosted by a combination of the QX and 793B vaccine (both with a ciliostasis score of 0 and 100% protection).

Sign in / Sign up

Export Citation Format

Share Document